American BioMed gets Investigational Device Exemption (IDE) for atherectomy trial:
This article was originally published in Clinica
American BioMed has received FDA permission for clinical trials of its atherectomy catheter, OmniCath. The US trial will investigate atherectomy in peripheral arteriovenous grafts. Its performance will be compared with balloon angioplasty.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.